Raloxifene detailed information

Raloxifene detailed information

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Evista
Pregnancy category	AU: X (High risk) US: X (Contraindicated)
Routes of administration	Oral
ATC code	G03XC01 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	2%
Protein binding	95%
Metabolism	Hepatic glucuronidation CYP system not involved
Elimination half-life	27.7 hours
Excretion	Fecal
Identifiers
IUPAC name [6-hydroxy-2-(4-hydroxyphenyl)- benzothiophen-3-yl]- [4-[2-(1-piperidyl)ethoxy]phenyl] -methanone
CAS Number	84449-90-1
PubChem CID	5035
DrugBank	APRD00400
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C28H27NO4S
Molar mass	473.584 g/mol

WikiDoc Resources for Raloxifene detailed information
Articles
Most recent articles on Raloxifene detailed information Most cited articles on Raloxifene detailed information Review articles on Raloxifene detailed information Articles on Raloxifene detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Raloxifene detailed information Images of Raloxifene detailed information Photos of Raloxifene detailed information Podcasts & MP3s on Raloxifene detailed information Videos on Raloxifene detailed information
Evidence Based Medicine
Cochrane Collaboration on Raloxifene detailed information Bandolier on Raloxifene detailed information TRIP on Raloxifene detailed information
Clinical Trials
Ongoing Trials on Raloxifene detailed information at Clinical Trials.gov Trial results on Raloxifene detailed information Clinical Trials on Raloxifene detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Raloxifene detailed information NICE Guidance on Raloxifene detailed information NHS PRODIGY Guidance FDA on Raloxifene detailed information CDC on Raloxifene detailed information
Books
Books on Raloxifene detailed information
News
Raloxifene detailed information in the news Be alerted to news on Raloxifene detailed information News trends on Raloxifene detailed information
Commentary
Blogs on Raloxifene detailed information
Definitions
Definitions of Raloxifene detailed information
Patient Resources / Community
Patient resources on Raloxifene detailed information Discussion groups on Raloxifene detailed information Patient Handouts on Raloxifene detailed information Directions to Hospitals Treating Raloxifene detailed information Risk calculators and risk factors for Raloxifene detailed information
Healthcare Provider Resources
Symptoms of Raloxifene detailed information Causes & Risk Factors for Raloxifene detailed information Diagnostic studies for Raloxifene detailed information Treatment of Raloxifene detailed information
Continuing Medical Education (CME)
CME Programs on Raloxifene detailed information
International
Raloxifene detailed information en Espanol Raloxifene detailed information en Francais
Business
Raloxifene detailed information in the Marketplace Patents on Raloxifene detailed information
Experimental / Informatics
List of terms related to Raloxifene detailed information

Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in certain high risk groups of females, [1] though with a reduced risk of thromboembolic events and cataracts in patients taking raloxifene versus those taking tamoxifen. On September 14, 2007, the U.S. Food and Drug Administration announced approval of raloxifene for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

There has been criticism in the mainstream oncology press of the way that information about the drug was released. There has been some confusion in the lay media about the meaning of the trial results. There is no specific clinical evidence for the use of raloxifene in the adjuvant treatment of breast cancer over established drugs such as tamoxifen or anastrozole.

Raloxifene is produced by Eli Lilly Pharmaceuticals and is sold under the brand name Evista®.

Description

Raloxifene hydrochloride (HCl) has the empirical formula C₂₈H₂₇NO₄S•HCl, which corresponds to a molecular weight of 510.05 g/mol. Raloxifene HCl is an off-white to pale-yellow solid that is slightly soluble in water.

SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the late

Indication

Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, and for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.

Contraindications and precautions

Raloxifene is contraindicated in lactating women or women who are or may become pregnant, in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis and in women known to be hypersensitive to raloxifene.

Adverse reactions

Common adverse events considered to be drug-related were hot flashes and leg cramps.

Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes.

As cancer drug

Raloxifene reduces the risk of hormone-positive breast cancer and vertebral fractures "without a shadow of a doubt," but its effects on cardiovascular disease remain less certain, according to the results of the "Raloxifene for Use of the Heart" (RUTH) study published in the July 13, 2006 issue of the New England Journal of Medicine by Dr. Elizabeth Barrett-Connor (University of California at San Diego) and colleagues.

In the trial, in women with coronary heart disease (CHD) or multiple risk factors for CHD, raloxifene had no significant effect on the primary end point, coronary events, but it did significantly increase the risk of venous thromboembolism (VTE). And although the drug had no effect on stroke, there was a seemingly paradoxical significant increase in death from stroke.

On September 14, 2007, Steven Galson, director of the United States Food and Drug Administration's Center for Drug Evaluation and Research announced authorization of the sale of raloxifene to prevent invasive breast cancer in post-menopausal women.

References

• Heringa M (2003). "Review on raloxifene: profile of a selective estrogen receptor modulator". Int J Clin Pharmacol Ther. 41 (8): 331–45. PMID 12940590.
• Barrett-Connor E. "Raloxifene: risks and benefits". Ann N Y Acad Sci. 949: 295–303. PMID 11795366.

External links

• STAR: a head-to-head comparison of tamoxifen and raloxifene as breast-cancer preventatives
• Full Prescribing Information
• Position paper of the National Women's Health Network